 |
 |
|
 |
||
 |
 |
|
 |
|
|
| Paul A. Godley, M.D., Ph.D.
Associate Professor |  |
Clinical Interests
Prostate Cancer, especially advanced disease
Testicular Cancer
Urothelial cancers, including bladder
Kidney Cancer
Penile Cancer
Research Interests
Dr. Godley is a clinically active medical oncologist and epidemiologist who conducts a wide spectrum of research in prostate cancer. In an NCI-funded study, he has studied nutritional risk factors for prostate cancer, examined utility of tissue measurements of fatty acid composition as objective markers of essential fatty acid consumption among cases and controls, and explored racial differences in these factors and markers. His initial emphasis was on omega-3 and omega-6 fatty acids. He is also conducting NCI-funded research on biomarkers of past consumption of fat-soluble vitamins. He is currently Principal Investigator of an ongoing American Cancer Society funded case-control study of prostate cancer screening which seeks to define the efficacy of PSA screening, and PI of a study using SEER and Medicare data to investigate racial differences in prostate cancer treatment outcomes.
At the University of North Carolina, Dr. Godley holds a variety of positions and administrative posts. He is an associate professor in the Division of Hematology/Oncology at the School of Medicine; is an adjunct associate professor in the Department of Epidemiology in the School of Medicine Public Health as well as in the Department of Biostatistics; and serves on numerous key committee, including chairing the School of Medicine Data and Safety Monitoring Board and sitting on the Admissions Committee. In 2001 Dr. Godley became Director of the Program on Ethnicity, Culture, and Health Outcomes (ECHO), a university initiative to advance understanding and elimination of racial health disparities through multidisciplinary research, education and training, and community partnerships. Godley is the co-chair of the Prostate Cancer Task Force of the North Carolina Advisory Committee on Cancer Coordination and Control and sits on the Prostate Committee of the CALGB (a national cancer clinical trials cooperative group). He is also Chairman of the Data and Safety Monitoring Committee for 2 large national prevention studies, the NCI-sponsored Prostate Cancer Prevention Trial and the NCI-sponsored SELECT prevention trial.
Dr. Godley is a recipient of the American Cancer Society Clinical Oncology Career Development Award and is a member of the American College of Physicians, American Society of Preventive Oncology, Society for the Epidemiologic Research, American Society of Clinical Oncology and American Society of Clinical Oncology and American Medical Association. In 2000 he took on the additional responsibility of an associate editorship for the Journal of the National Cancer Institute and sits on the ACS study section, "Clinical Research, Cancer Control and Epidemiology."
After graduating magna cum laude from Yale University, Dr. Godley concurrently earned his MD degree from Harvard Medical School and a Master of public policy degree from Harvard's John F. Kennedy School of Government. He completed his internship and residency at the Case Western Reserve University Hospitals, University Hospitals of Cleveland and the Cleveland VA Medical Center. He continued on to the University of North Carolina research fellowship in cancer epidemiology and a fellowship in hematology/oncology. While completing his fellowship training, Dr. Godley also earned a Ph.D. degree in epidemiology at the university.
His most recently awarded grants are from the Agency for Health Care Research and Quality, where he is Co-PI of the program project grant, "Eliminating Racial Disparities in Health," and from the Centers for Disease Control where he is PI of a constituent case-case project comparing prostate cancer outcomes among African Americans and Caucasians.
Training
Harvard Medical School M.D. 1984
University of North Carolina Ph.D. 1993
Board Certifications
Internal Medicine 1987
Oncology 1992
Publications
Godley P, Rathore S, Kshiragar A, Amamoo A, Schell M, Freeman J, et al: Retrospective classification of prostate-specific antigen tests: differentiating screening from diagnostic clinical encounters. J Clin Epidemiol; In Press, 2001.
Savarese DM, Halabi S, Hars V, Akerley WL Taplin, M-E, Godley PA, Hussain A, Small EJ, and Vogelzang NJ. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol; 19:2509-16, 2001.
Godley PA, Taylor M: Renal cell carcinoma. Curr Opin Oncol; 13:199-203, 2001.
Kornblith AB, Herndon JE, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ. The impact of docetaxel, estramustine and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and thier partners: A Feasibility Study. Ann Oncol; 12:633-41, 2001.
Godley, P.A., and Schell, J.M. Adjusted Odds Ratios Under Non-differential Misclassifcation: Application to Prostate Cancer. J Clin Epidemiology, 52: 129-136, 1999.
Godley, P. Prostate cancer screening: promise and peril. Cancer Detect Prev, 23(4):316-324, 1999.
Godley, P. A. Hepatocellular Carcinoma. In: J. Johanson (ed.),Gastrointestinal Diseases: Risk factors and prevention, pp. 265-278. Philadelphia: Lippincott-Raven, 1997.
Godley PA, Campbell MK, Miller C, et al. The Correlation of Erythrocyte Membrane and Adipose Tissue Biomarkers of Omega-3 Fatty Acid Consumption with Questionnaire Data in Black and White US Males with and without Prostatic Carcinoma. Cancer Epidemiol Biomarkers Prev; 5: 115-119, 1996.
Godley PA , Campbell MK, Gallagher P, Martinson F, Mohler JL, and Sandler RS. Biomarkers of Essential Fatty Acid Consumption and Risk of Prostatic Carcinoma. Cancer Epidemiol Biomarkers Prev, 5: 889-895, 1996.
Godley PA. Essential Fatty Acid Consumption and Risk of Breast Cancer. Breast Cancer Res and Treatment, 35(1):91-95, 1995.
Godley PA, Sandler RS. Liver cancer. In: Everhart JE (ed). Digestive Diseases in the United States: Epidemiology and Impact. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, NIH publication no. 94-1447, pp 225-246, 1994.
Godley PA. Biomarkers of essential fatty acid consumption and risk of prostate cancer. Doctoral Dissertation, University of North Carolina at Chapel Hill, Department of Epidemiology. 1993
Kaluzny A, Brawley O, Garson-Angert D, Shaw J, Godley P, Warnecke R and Ford L. Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program. J Natl Cancer Inst. 85:1945-50, 1993.
Godley, PA. Cancer in Special Populations. Chapter V In: Leading Causes of Mortality. North Carolina Vital Statistics 1988 (Volume II). Center for Health and Environmental Statistics, North Carolina Department of Environment, Health and Natural Resources. Raleigh, 37-43, 1990.
E-mail: pgodley@med.unc.edu
Telephone: (919) 966-4431
FAX: (919) 966-6735
Address: 3009 Old Clinic Bldg. Chapel Hill, NC
